JP2010513441A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513441A5
JP2010513441A5 JP2009542206A JP2009542206A JP2010513441A5 JP 2010513441 A5 JP2010513441 A5 JP 2010513441A5 JP 2009542206 A JP2009542206 A JP 2009542206A JP 2009542206 A JP2009542206 A JP 2009542206A JP 2010513441 A5 JP2010513441 A5 JP 2010513441A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
hal
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513441A (ja
JP5431954B2 (ja
Filing date
Publication date
Priority claimed from GBGB0625523.6A external-priority patent/GB0625523D0/en
Application filed filed Critical
Publication of JP2010513441A publication Critical patent/JP2010513441A/ja
Publication of JP2010513441A5 publication Critical patent/JP2010513441A5/ja
Application granted granted Critical
Publication of JP5431954B2 publication Critical patent/JP5431954B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542206A 2006-12-21 2007-12-19 InVivo造影剤 Expired - Fee Related JP5431954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625523.6 2006-12-21
GBGB0625523.6A GB0625523D0 (en) 2006-12-21 2006-12-21 In vivo imaging agents
PCT/GB2007/004880 WO2008075040A2 (en) 2006-12-21 2007-12-19 In vivo imaging agents

Publications (3)

Publication Number Publication Date
JP2010513441A JP2010513441A (ja) 2010-04-30
JP2010513441A5 true JP2010513441A5 (enExample) 2011-01-13
JP5431954B2 JP5431954B2 (ja) 2014-03-05

Family

ID=37734613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542206A Expired - Fee Related JP5431954B2 (ja) 2006-12-21 2007-12-19 InVivo造影剤

Country Status (8)

Country Link
US (3) US20110129419A1 (enExample)
EP (1) EP2125038B1 (enExample)
JP (1) JP5431954B2 (enExample)
CN (1) CN101678129B (enExample)
AT (1) ATE555814T1 (enExample)
ES (1) ES2384002T3 (enExample)
GB (1) GB0625523D0 (enExample)
WO (1) WO2008075040A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
JP5656408B2 (ja) 2006-12-26 2015-01-21 ランセウス メディカル イメージング, インコーポレイテッド 心臓の神経支配を画像化するためのリガンド
EP2036578A1 (en) * 2007-09-13 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
RU2710736C2 (ru) 2010-05-11 2020-01-10 Лантеус Медикал Имэджинг, Инк. Композиции, способы и системы для синтеза и применение визуализирующих средств
CN101921224B (zh) * 2010-05-21 2012-01-18 中国人民解放军军事医学科学院生物工程研究所 1-(3-氨基丙基)哌嗪-4-氨基酰胺类化合物及其制备方法与应用
US9649394B2 (en) * 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
KR102527562B1 (ko) * 2011-09-09 2023-05-03 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP3493855A4 (en) 2016-08-02 2020-04-01 ISI Life Sciences, Inc. METHOD FOR DETECTION OF CANCER CELLS.
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310621A (zh) * 1998-07-28 2001-08-29 史密丝克莱恩比彻姆公司 取代的n-酰苯胺化合物和方法
TR200103214T2 (tr) * 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
PE20010628A1 (es) * 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
NZ519183A (en) * 1999-12-03 2005-02-25 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SK1142003A3 (en) * 2000-07-31 2003-06-03 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11CBY receptor
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
GB0115929D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
SE0103819D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
WO2006102395A2 (en) 2005-03-22 2006-09-28 Medstar Health Inc Delivery systems and methods for diagnosing and treating cardiovascular diseases

Similar Documents

Publication Publication Date Title
JP2010513441A5 (enExample)
JP2013528180A5 (enExample)
JP2006507265A5 (enExample)
JP2020514300A5 (enExample)
JP2007511494A5 (enExample)
JP2004516314A5 (enExample)
JP2010523599A5 (enExample)
KR101639268B1 (ko) 18 f-표지된 폴레이트
JP2006526646A5 (enExample)
JP2009535358A5 (enExample)
JP5431954B2 (ja) InVivo造影剤
JP2008504292A5 (enExample)
JP2009526034A5 (enExample)
JP2011529919A5 (enExample)
JP2009530424A5 (enExample)
JP2014519507A5 (enExample)
US10973936B2 (en) 18F-saccharide-folates
US20250222122A1 (en) Psma targeted conjugate compounds and uses thereof
JP2007500730A5 (enExample)
JP2018530582A5 (enExample)
JP2020505354A5 (enExample)
JP2009538894A5 (enExample)
JP2010518158A5 (enExample)
JP2006516643A5 (enExample)
JP2012504581A5 (enExample)